reports
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
ANI Pharmaceuticals Announces Presentation of New Preclinical Data The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse model of murine collagen-induced inflammatory arthritis. “In a preclinical model ...
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare...
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: Date:Wednesday, June 4, 2025 Time:2:35pm ET Webcast: To schedule a 1x1 meeting with the Company, please contact your Jefferies representative at . The live and archived webcast will be accessible from the Company’s website at , under the Inv...
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of ...
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Pha...
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual B...
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: Date:Tuesday, May 20, 2025 Time:1:30pm ET Webcast: To schedule a 1x1 meeting with management, please contact The live and archived webcast will be accessible from the...
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Result...
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% yea...
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the ...
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. “In a...
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on...
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows...
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmolo...
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference as follows: Date:Thursday, April 3, 2025Time:7:45am ETWebcast: The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay...
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug (RLD) Alinia®. "The market launch of Nitazoxanide Tablets, another niche limited competition product, underscores our purpose of ‘Serving Patients, Improving Lives’,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "We share ANI’s commitment to providin...
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN...
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® BAUDETTE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC (SWK) on worldwide net revenues of ILUVIEN and YUTIQ for a one-time payment of $17.25 million. Under the terms of the agreement, upon making the buyout payment, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward. ANI funded the buyout with cash on hand. ...
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® L...
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME)ANI plans to begin marketing ILUVIEN in the U.S. under the combined label later this year BAUDETTE, Minn., March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal ...
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin ...
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in a prefilled syringe format. This new presentation will be available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through Cortrophin Gel’s established specialty pharmacy network. The prefilled syringe reduces administ...
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 F...
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0 million, which includes: Record quarterly net revenue for Purified Cortrophin® Gel of $59.4 million, an increase of 42.3% year-over-year, andILUVIEN® and YUTIQ® net revenues of $27.6 million in the first full quarter of ownership following the acquisition of Alimera Sciences Delivered record quarterly adjus...
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investo...
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates’ 46th Annual Institutional Investors ConferenceTuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare ConferenceTuesday,...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Finan...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference cal...
- Dave Nicoski
- Ross LaDuke
TWI TITAN INTERNATIONAL INC.
TRIP TRIPADVISOR INC.
TITN TITAN MACHINERY
SLP SIMULATIONS PLUS
RYI RYERSON HOLDING CORPORATION
QCOM QUALCOMM INC
PCRX PACIRA BIOSCIENCES INC.
MOS MOSAIC COMPANY
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
IVZ INVESCO LTD.
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
DLTR DOLLAR TREE INC.
DDD 3D SYSTEMS CORPORATION
CERS CERUS CORP.
AVD AMERICAN VANGUARD
ANIP ANI PHARMACEUTICALS INC.
AGCO AGCO CORPORATION
UPS UNITED PARCEL SERVICE INC. CLASS B
OSTK OVERSTOCK.COM INC.
GDEN GOLDEN ENTERTAINMENT
FRX_CN FENNEC PHARMACEUTICALS
ODEL.N0000 ODEL PLC
BRKS BROOKS AUTOMATION INC.
CCV COUNTERPATH
TDC TERADATA CORPORATION
BHF BRIGHTHOUSE FINANCIAL INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
SIBN SI-BONE
PINS PINTEREST INC. CLASS A
VIAC VIACOMCBS INC. CLASS B
ORIC ORIC PHARMACEUTICALS
THRY THRYV HOLDINGS
CERT CERTARA
ONTF ON24
SMTI SANARA MEDTECH
SDGR SCHRODINGER
COUR COURSERA INC
BBWI BATH & BODY WORKS INC
DH DEFINITIVE HEALTHCARE CORP
VERV VERVE THERAPEUTICS INC
PTLO PORTILLOS INC
DCGO DOCGO INC
EHAB ENHABIT INC
SVV SAVERS VALUE VILLAGE INC
QIPT PATIENT HOME MONITORING CORP
HUM HAMILTON U.S. MID-CAP FINANCIALS ETF
CXM SPRINKLR INC
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows: Date:Wednesday, February 5, 2025Time:2:00pm ESTWebcast: The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentation...
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Finan...
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with Purified Cortrophin Gel net revenues of $197.8 million to $198.4 million for the full year 2024 and ILUVIEN and YUTIQ net revenues of $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31,...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopr...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. "We are delighted to build momentum early in 2025 with the approval of the fir...
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthca...
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco. The live and archived webcast will be accessible from the Company’s website at , under the Inves...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.